Semax typical research dosing
Across the available literature, Semax is most commonly administered at 200–600 mcg per dose, 2 time(s) per day, via nasal injection. Semax is most commonly administered intranasally (1–2 drops per nostril of a 0.1% or 1% solution). Research protocols typically use 200–600 mcg per dose, one to two times daily. Injectable formulations also exist but are less common in research settings outside clinical trials.
Semax unit-conversion table
The number of insulin-syringe units you draw depends on how much bacteriostatic water you used to reconstitute the vial. The table below shows units to draw on a U-100 syringe for a 0.5 mg Semax vial at common reconstitution volumes.
| Diluent (mL) | Concentration | 200 mcg | 400 mcg | 600 mcg |
|---|---|---|---|---|
| 1 mL | 500 mcg/mL | 40.0 units | 80.0 units | 120.0 units |
| 2 mL | 250 mcg/mL | 80.0 units | 160.0 units | 240.0 units |
| 3 mL | 167 mcg/mL | 120.0 units | 240.0 units | 360.0 units |
| 5 mL | 100 mcg/mL | 200.0 units | 400.0 units | 600.0 units |
Semax cycle length
Most reported Semax protocols run 4 weeks on, then 2 weeks off. Cycles are used in research to study washout, receptor sensitivity, and to re-baseline endogenous signaling before re-introducing the compound.
Semax half-life and timing
Semax has a half-life of approximately 0.1 hours. This influences dose frequency: shorter half-lives often require multiple doses per day to maintain steady-state levels, while longer half-lives can be dosed less frequently.